REFERENCES / BIBLIOGRAPHY:

A. BOOKS:

1) D Harvey, (**2000**), Modern Analytical Chemistry, Mc-Graw-Hill higher education publication, P. Nos. 798-03.

2) G Gauglitz, T Vo-dinh, (**2003**), Handbook of Spectroscopy, Wiley-VCH verlag GmbH and co. P.Nos 538-42.

3) Guidance for industry: Q3A Impurities in new Drug Substances.

4) ICH Guideline, alidation of Analytical Procedures: Text & Methodology Q2 (R1).

5) JB Lambert, EP Mazola, (**2004**), Nuclear Magnetic Resonance Spectroscopy, An Introduction to principles, Applications and Experimental methods,Pearson Education Inc. P.Nos. 341-45.

6) JMHollis, (**2004**), Modern Spectroscopy, 4th Edn., Wiley & Sons, P.Nos. 452.

7) MW Dong, (**2006**),Modern HPLC for Practicing Scientists, Dynamics pharmaceutical service LLC, Wiley Interscience John Wiley. P.Nos. 286-295.

8) PK Braithwaite,FJ Smith, (**1999**), Chromatographic methods, Kluwer Academic publishers,5th Edn.,P. Nos. 559-65.

B. RESEARCH ARTICLES:

1) A Mukherjee, A Bera, (**2012**), A Detailed Study of Validation Parameters & System Suitability Test in HPLC. Res.J.Pharm., Biol. Chem. Sci. 3(4): 432-47.

2) AW Newmann, SR Byrn, (**2003**), Solid-state analysis of the active pharmaceutical ingredients in drug products in Drug discovery Today. 8(19): 898-05.

3) A.Ayre, D Varpe, R Nayakl, N Vasa2, (**2011**), Impurity profiling of pharmaceuticals in Dr. L H Hiranandani coll. Of Pharm, 1(2):ISSN2250-0744.

4) B Raman, BA Sharma, PD Ghugare, PP Karmuse, A Kumar, (**2009**), Semi-preparative isolation & structural elucidation of an impurity in citalopram by LC/MS/MS. J. Pharm. Biomed. Anal. 27(19): 55-60.

5) CH Krishnaiah, AR Reddy, R Kumar, K Mukkanti, (**2010**), Stability-indicating UPLC methods for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms in J. pharm, Bio. Anal. 53(3):483-89.

6) C Ashok, M Golak, D Adwait, V Krishna, P Umesh, G Amol, S Srinivas, M Sharad, J Deepali, C Atul, (**2009**), Isolation and structural elucidation of two impurities from a diacerein bulk drug in J. Pharm. Bio. Anal. 49(2):525–28.

7) D OM, G AI, S GG, W DG, (**2000**), Isolation and identification of three potential impurities of pholcodine bulk drug substance in J. Pharm. Pharm. 52(7):819-29.

8) Derek I. Robinson, (**2010**), Control of Genetoxic Impurities in Active Pharmaceutical Ingredients, Org. 14(4):946-59.

9) E Rogatsky, V Tomuta, DT Stein, (**2006**), Validation in context of bioanalytical research papers. J. Sepa.Sci. 29, 2555 – 56.

10) GVR Reddy, AP Kumar, BV Reddy, J Sreeramulu, (**200**9), Application of ion-trap mass spectrometry for identification and structural determination of an unknown impurity in simvastatin. Pharmazie. 64 (10):638-41.

11) GM Reddy, B V Bhaskar, P P Reddy, P Sudhakar, J M Babu, K Vyas, P R Reddy, K Mukkanti, (**2007**), Identification and characterization of potential impurities of raberprazole sodium in J. Pharm, Bio. Anal. 43(4):1262-69.

12) I Colon, SM Richoll, (**2005**), Determination of methyl & ethyl esters of methansulfonic, benzenesulfonic & toluenesulfonic acids in API by solid-phase micro-SPME coupled to GS/SIM-MS., J.Pharm.Bio.Anal.39 (3):477-85.

13) J Diana, C Govaerts, J Hoogmartens, AV Schepdael, E Adams, (**2006**) , Characterization of impurities in dirithromycin by liquid chromatography/ion trap mass spectrometry. J. Chromato. A.1125 (1):52-66 .

14) J Kovaleski, B Kraut, A Mattiuz, G Brobst, W Cagno, P Kulkarni, T Rauch, (**2007**), Pharmaceutical Impurities:Analytical, Toxicological and Regulatory Perspectives in Adv. Drug Delivery Reviews. 59(1):56-63.

15) K Pilaniya, HK Chandrawanshi, U Pilaniya, P Manchandani, P Jain, N Singh, (**2010**), Recent trends in the impurity profile of pharmaceuticals. J. Adv. Pharm. Technol. Res. 1(3): 302–310.

16) Kenneth R Morris, U J Griesser, C J Eckhardt, J G Stowell,(**2001**), Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes in Adv. Drug Delivery Rev.,. 48(1):91-114.

17) MV Lokhande , MK Gupta, NG Rathod,(2013), Characterization And Quantitative Determination Of Process Related Impurities In Sulfamethoxypyrazine By Some Analytical Techniques, Inter. J.Med.Pharm. Sci.,3(4): 37-48.

18) MV Lokhande, NG Rathod, MKumar Gupta,(**2013**), Identification and structural elucidation of process related impurities in duloxetine hydrochloride, Inter. J. Chem. Pharm. Sci. 4 (2):34-43.

19) MV Lokhande, NG. Rathod , MKumar Gupta, (**2013**), Structural elucidation, Identification, quantization of process related impurity in Hydralazine HCl, HR/AM- LC MS/MS, NMR and FTIR technique. J. Appl. Chem. 6(2): 05-15.

20) M Bakshi, S Singh, (**2002**), Development of Validated stability-indicating assay methods in J. Pharm, Bio. Anal. 28(6):1011-40.

21) NG Rathod, MV Lokhande, (**2014**), Identification Of Impurities Related To Amodiaquine Hydrochloride By Using Some Analytical Techniuqes . Wor. J. Pharm. Res., 3(6),1739-58.

22) N Blagden, M de Matas, P T Gavan, P York, (**2007**), Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates in Adv.Drug Delivery Reviews. 59(7):617-630.

23) N Venugopal, A V B Reddy, K G Reddy, V Madhavi, G Madhavi, (**2012**), Method development and validation study for quantitative determination of 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride a genetoxic impurity in Pantaprazole API by LC/MS/MS., J. Pharm, Bio. Anal. 70:592-97.

24) N Mistry, IM Ismail, MS Smith, JK Nichilson, JC Lindon, (1**997**), Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC–NMR spectroscopy and HPLC–MS in J. Pharma, Bio. Anal. 16(4):697-05.

25) P Zhu, D Wang, C Sun, Z Shen,(**2008**),Characterization of impurities in the bulk drug lisinopril by liquid chromatography/ion trap spectrometry. J. Zhejiang. Univ. Sci. B, 9(5): 385–90.

26) RS Deshmukh, AR Umarkar, SR Bavaskar, PS Narkhede,VG Chaudhari , MG Dhande, (**2011**), Impurity Profile in Pharmaceutical Substances- A Comprehensive: A Review, Inter. J. Pharm. Biol. Sci. 1(4):382-92.

27) S Thomas, CS Mathela, A Agarwal, SK Paul,(**2011**), Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation. J. Pharma. Biomed. Anal.56 (2):423-28.

28) SR Chembuakar, J Bauer, K Deming, H Spiwek, K Patel, J Quick, P Bauer, J Donaubauer, B A Narayan, M Soldani, D Riley, K Mc Farland, (**2000**), Dealing with the Impact of Ritonavir Polymorphs on the late stages of Bulk Drug process Development in process Development and Anal.Res.Abbort Lab.1401 Sherian Rd, North Chicago Illinois.92,2484.

29) SB Bari, BR Kadam, S Jaiswal, AA Shirkhedkar, (2007), Significance in Active pharmaceutical Ingredient in Eurasian, J.Anal. Chem. 2(1).

30) S L Prabul, TNK Suriyaprakash, (**2010**), Impurities and its importance in pharmacy in. Intern. J. Pharm, Sci Review and Research. 3(2):66.

31) T Radhakrishna, J.Satyanarayan, (**2002**), LCdetermination of resolitazone in Bulk and Pharma. Formulation.,J. Pharma, Bio. Anal. 29(5): 873-80.

32) Takashi Mukuta, A Y Lee, T Kawakani, A S Myerson, (**2005**), Influence of Impurities on the solution –Mediated Phase Transformation of an Active Pharmaceutical Ingredients in Dept. of chem. and Environ. Engg. Illinois Inst. of Tech. Chicago. 5(4):1429-36.

33) T W Ryan, (**1998**), Identification of Four Process-Related Impurities in the Bulk Drug Butalbital Using HPLC-UV Photodiode Array Detection, Particle Beam MS, and NMR in Anal. Letter., 31(14): 2447-56.

34) VG Dongre, PP Karmuse, PD Ghugare, SK Kanojiya, S Rawal, (**2008**), Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap ms. Rapid. Comm. Mass.Spectr.22 (14): 2227-33.

35) VG Dongre, PP Karmuse, PP Rao, A Kumar, (**2008**), Development and validation of UPLC method for determination of primaquine phosphate and its impurities. J.Pharm. Biomed. Anal.46 (2):236-42.

36) VG Dongre, PP Karmuse , PD Ghugre, SM Salunke, A Kumar, (**2006**), Preparative isolation and structural elucidation of impurities in fluconazole by LC/MS/MS. J. Pharm. Biomed. Anal. 26;42(3):334

37) VG Dongre, PP Karmuse, PDGhugare, MGupta, CShaha, Akumar, (**2007**), Characterization & quantitative determination of impurities in piperaquine phosphate by HPLC& MS.J.Pharma. Biomed. Anal..43(1):186-95.

38) VG Dongre, PD Ghugare, P Karmuse, D Singh, A Jadhav, A Kumar, (**2009**),Identification and characterization of process related impurities in

chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR. J. Pharm. Biomed. Anal.. 49(4):873-9.

39) YZ Yuan, M Zhang, XLFan, GH Wang, CQ Hu, SH Jin, E Adams, (**2012**), Impurity profiling of etimicin sulfate by liquid chromatography ion-trap mass spectrometry. J. Pharm. Biomed. Anal. 7-10(1): 22-28.

40) Y Peng, J Luo, Q Lu, X Chen, Y Xie, L Chen, W Yang, S Du, (2009), HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug in J. Pharm, Bio. Anal. 49(3):828–832.

C. PATENTS:

1. P Bhandari, LS Shashidhara, (2002)In Vivo Assay System For Screening And Validation Of Drugs And Other Substances, US 2002/0184656 A1, Patent Application 09/987,48.
2. STC Wong, H Zhao, G Jin, (2012), Drug Repositioning Methods For Targeting Breast Tumor Initiating Cells, US 20120296090 A1. Application No. US 13/439,626.
3. WD Craig, PJ Brandon, SP Peter , MM Graves, (2012), Method, system and apparatus for dispensing drugs, EP 2 261 828 A3., European Patent Application 10176201.1.